Cure My Disease

Don't miss your cure!

 Log in / Sign up

Leqvio's Real-World safety under the microscope in 1,500 patients

NCT ID NCT06770543

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 10, 2026 · Last updated May 12, 2026 · Updated 15 times

Summary

This study is a required safety check by Korean health authorities for the drug Leqvio (inclisiran), used to lower cholesterol. It will follow 1,500 adults with high cholesterol who are already prescribed Leqvio in regular clinics. The main goal is to track any side effects and see how well the drug controls cholesterol levels over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Yangsan, Gyeongsangnam-do, 50612, South Korea

  • Novartis Investigative Site

    RECRUITING

    Busan, 49241, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 04763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Taegu, 41944, South Korea

Conditions

Explore the condition pages connected to this study.

PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA